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Background. The aim of this report was to evaluate the clinical profile and previous management of patients with uncontrolled
neuropathic pain who were referred to pain clinics.Methods.We included adult patients with uncontrolled pain who had a score of
≥4 in the DN4 questionnaire. In addition to sociodemographic and clinical data, we evaluated pain levels using a visual analog scale
as well as anxiety, depression, sleep, disability, and treatment satisfaction employing validated tools. Results. A total of 755 patients
were included in the study. The patients were predominantly referred to pain clinics by traumatologists (34.3%) and primary care
physicians (16.7%).Themost common diagnoses were radiculopathy (43%) and pain of oncological origin (14.3%).Themajor cause
for uncontrolled pain was suboptimal treatment (88%). Fifty-three percent of the patients were depressed, 43% had clinical anxiety,
50% rated their overall health as bad or very bad, and 45% noted that their disease was severely or extremely interfering with
their daily activities. Conclusions. Our results showed that uncontrolled neuropathic pain is a common phenomenon among the
specialties that address these clinical entities and, regardless of its etiology, uncontrolled pain is associated with a dramatic impact
on patient well-being.
1. Introduction
Neuropathic pain is defined as pain that originates from a
lesion or disease that affects the somatosensory pathways
within the peripheral or central nervous system [1]. Neuro-
pathic pain is common among the general population, with
prevalence rates of 7-8% [2, 3]. Neuropathic pain, which
is also a common occurrence (12%) among patients who
are managed by primary care physicians [4], accounts for
a high proportion (20%) of the patients who are referred
to specialized pain units [5]. The causes of neuropathic
pain comprise a wide and heterogeneous number of clinical
conditions, such as diabetic neuropathy, complex regional
pain syndrome, spinal cord injury pain, postherpetic neural-
gia, postoperative pain, trigeminal neuralgia, drug-induced
polyneuropathies, HIV-associated neuropathy, multiple scle-
rosis, and central pain syndromes secondary to vascular
lesions [6, 7]. Although it may be acute in nature, in the vast
majority of patients, neuropathic pain is a chronic condition.
Regardless of its etiology, neuropathic pain is disabling and
substantially impairs patients’ health-related quality of life
[8–12]. This condition is associated with high societal costs
because of the patients’ loss of productivity and increased
utilization of health resources [8, 10, 13–15].
Managing neuropathic pain requires an interdisciplinary
approach in which pharmacological treatment is fundamen-
tal [5, 16]. Despite the availability of several effective drugs,
neuropathic pain treatment is challenging: response to treat-
ment is unpredictable; despite the fact that the patients may
receive several drugs for pain treatment, moderate-to-severe
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levels of pain are common; suboptimal treatment is also
common with patients who receive ineffective treatments,
such as nonsteroidal anti-inflammatory drugs or lower-than-
recommended doses of the prescribed treatment; and delayed
referral to pain clinics is also common [4, 8, 16–18].
Although there is consensus that many patients with
neuropathic pain do not respond adequately or are unable
to tolerate existing treatments [19, 20], epidemiologic infor-
mation about this population is limited [21]. The aim of
this report was to evaluate the clinical profile and previous
management of patients with uncontrolled neuropathic pain
who were referred to pain clinics.
2. Patients and Methods
2.1. Study Design, Setting, and Patients. This report was an
observational, multicenter, and prospective study performed
by 161 investigators from pain clinics throughout Spain
between February 2009 and February 2010. The study was
approved by the Ethics Committee of the Hospital General
Universitario de Valencia (Spain). Written informed consent
was obtained from every subject.The study was conducted in
accordance with the principles of the Declaration of Helsinki.
In this report, we presented the baseline (cross-sectional) data
of the study.
For inclusion in the study, the patients had to fulfill
the following criteria: age 18 years or older; referral to a
pain clinic because of uncontrolled pain; and a score of
equal to or greater than 4 in the DN4 questionnaire. The
patients were excluded from the study if they were unable
to understand the study objectives or complete the self-
administered questionnaires.
2.2. Study Assessments. At baseline, the following informa-
tion was recorded: sociodemographic data, type of specialist
referring the patient, diagnostic confirmation of neuropathic
pain, confirmation of the presence of uncontrolled pain as
assessed by the investigator, etiology and duration of pain,
causes for uncontrolled pain, pain intensity as measured
using a 0 to 100mm visual analog scale (VAS), and signs
and symptoms of neuropathic pain. We also recorded phar-
macological and nonpharmacological treatment for neuro-
pathic pain. Additionally, the Spanish validated versions
of the following questionnaires and scales were completed:
DN4 questionnaire, Hospital and Anxiety Depression Scale
(HADS), the Medical Outcomes Study Sleep (MOS Sleep)
Scale, the World Health Organization Disability Assessment
Schedule (WHO-DAS II), and the Treatment Satisfaction
with Medicines Questionnaire (SATMED-Q).
The neuropathic pain diagnostic questionnaire DN4 con-
sists of 10 items that describe different pain characteristics. A
score of at least 4 of 10 possible points is considered acceptable
to identify neuropathic pain with 83% sensitivity and 90%
specificity [22–24].
The HADS, which is a self-administered instrument,
consists of 14 items: 7 items that refer to depression symptoms
and 7 items that refer to anxiety symptoms [25, 26]. Each
item score ranges from 0 to 3, where 0 represents the absence
of that symptom and 3 represents the highest severity or
frequency of the symptom. By adding the 7 items of each
subscale, two scores ranging from 0 to 21 are obtained that
represent depression and anxiety (HADS-D and HADS-A),
respectively.
The MOS Sleep Scale, a self-administered questionnaire,
evaluates the key aspects of sleep [27, 28] and consists
of 12 items that comprise six subscales or domains: sleep
disturbances, snoring, shortness of breath or headache upon
awakening, adequacy of sleep, day somnolence, and amount
of sleep. Additionally, the MOS Sleep Scale provides a
summary index of sleep disturbances that can be obtained
from 9 of its items; the higher the score is, the worse the sleep
is, with the exception of amount of sleep and adequacy of
sleep dimensions, which are scored in the opposite direction.
In patients with neuropathic pain, this scale has shown to
have appropriate psychometric properties [28].
The WHO-DAS II comprises 12 items that evaluate an
individual’s level of functioning and disability in six areas:
understanding and communicating, getting around, self-
care, getting along with people, life activities, and participa-
tion in society [29–31]. The patients are required to answer
questions regarding how many difficulties they experienced
in the last 30 days as a result of their health condition, using
a five-point scale from 1 (none) to 5 (extreme difficulty or
cannot do it). The raw scores are transformed into a standard
scale that ranges from 0 to 100; the higher scores reflect more
severe disability. A global score is obtained that ranges from
0 to 700 (if work activities outside the home are assessed) or
from 0 to 600.
The SATMED-Q, a self-administered questionnaire, con-
sists of 17 items that evaluate six dimensions: treatment
effectiveness, convenience of use, impact on daily activities,
medical care, global satisfaction, and undesirable side-effects
[32, 33]. The questionnaire also provides a global score for
satisfaction with drug treatment by summing the scores of all
of the domains. The raw scores are transformed into a scale
that ranges from 0 to 100; the higher scores indicate greater
satisfaction. Questions on medication side-effects include
whether the patient experienced side-effects and whether the
side-effects interfered with their physical exercises, leisure
time, and daily activities.
2.3. Statistical Analysis. The analysis was essentially descrip-
tive using the means and standard deviations for quantitative
variables and using the absolute and relative frequencies for
qualitative variables. The patients were categorized as having
clinical anxiety or depression if they had a score equal or
greater than 11 in the anxiety or depression subscales of the
HAD.
3. Results
We included 755 patients in the study. We excluded 27 (3.6%)
patients who did not meet the selection criteria, thereby
leaving 728 evaluable patients.
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Specialty
Primary care
Traumatology
Neurology
NeurosurgeryRehabilitation
Rheumatology
Other surgeries
Other specialties
n = 36
5,1%
n = 32
4,5%
n = 62
8,8%
n = 58
8,2%
n = 56
7,9%
n = 242
n = 118
n = 102
34,3%
16,7%14,4%
(a)
Causes of neuropathic pain
Neuropathy Neuralgia
Radiculopathy Nerve entrapment syndrome
Plexopathy Complex regional pain syndrome
Postsurgery/trauma Malignant/radiation/
Central neuropathic pain
Other neruopathic pain
n = 56
n = 298
n = 21
n = 99
n = 24
n = 36
n = 54
n = 39
n = 17 n = 48
8,1%
2,5% 6,9%
5,6%
3,5%
7,8%
3,0%
5,2%
43,1%
14,3%
chemotherapy-induced pains
(b)
Figure 1: Specialists referring patients and clinical entities referred to pain clinics.
3.1. General Characteristics of Patients. The patients had a
mean age of 57 years, were predominantly women (61%), and
exhibited obesity in a high proportion (20%) (Table 1). More
than one-third of the patients were referred to pain clinics
by traumatologists, followed by those who were referred by
primary care physicians (Figure 1).
3.2. Pain Characteristics and Treatment. The patients had
severe pain with a mean score of 75 using the VAS; the
duration of pain was generally 2,6 years and was longer for
those patients who were referred to pain clinics from the
departments of rheumatology, neurosurgery, and neurology
(Table 2). The majority (43%) of the patients were diagnosed
with radiculopathy (Figure 1), which was the predominant
diagnosis among those patients referred by traumatology,
neurosurgery, rheumatology, and rehabilitation departments
(Table 2).The patients who were referred by neurologists had
trigeminal neuralgia and central neuropathic pain as their
primary diagnoses, whereas primary care physicians referred
patients with oncological pain or radiculopathy. The type,
spontaneous or evoked, and subtypes of pain by clinical entity
are presented in Table 3. All subtypes of spontaneous pain
were present in more than 80% of the patients, regardless
of the clinical entity. The subtypes of evoked pain were less
represented, especially thermal allodynia; however, nearly
every subtype was present in more than two-thirds of the
patients in every clinical entity.
The major cause for uncontrolled pain, as assessed by
the pain clinic investigators, was attributed to suboptimal
treatment (88%) because of the use of ineffective drugs or
subtherapeutic doses (Table 2). The use of ineffective drugs
was less common among the patients who were referred by
the neurology and neurosurgery departments.
The patients were receiving a mean of 3 drugs; one-
third of the patients, regardless of the referral specialty, were
receiving 4 or more drugs (Table 4). The most common
prescribed drugs were antiepileptics (54%), opiods (40%),
and nonsteroidal anti-inflammatory agents (40%); the latter
drugs were more commonly prescribed by specialists in
rehabilitation facilities (55%), rheumatologists (50%), and
traumatologists (46%) and were less commonly prescribed
by neurologists (28%) and primary care physicians (34%).
Table 5 shows the doses and treatment duration of the most
common drugs that patients were receiving at the time of
referral.
Patients with uncontrolled pain showed low satisfaction
with their treatment with a global satisfaction score of 44 of
100. Treatment effectiveness and the impact of medicine on
their everyday lifewere the areas exhibiting lower satisfaction,
with mean scores of 32 and 30, respectively (Table 6).
The number of drugs that the patients were receiving
was higher among the patients with central neuropathic
pain (3.7), plexopathy (3.5), radiculopathy (3.3), and com-
plex regional pain syndrome (3.2) and was lower among
those with diabetic neuropathy (2.3) (Table 7). The use of
antiepileptics, especially carbamazepine and oxcarbazepine,
was higher in patients with trigeminal neuralgia (90.6%);
the use of opioids was higher in patients with plexopathy
(50%), nerve entrapment syndrome (46%), and radiculopa-
thy (45%). Approximately 50% of the patients with radicu-
lopathy, nerve entrapment syndrome, or complex regional
syndrome were receiving NSAIDs. Suboptimal treatment
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Table 5: Most common (≥5%) drugs for the treatment of neuropathic pain at the time of referral.
Drug % patients Mean dose (SD)mg/day
Duration (months)
mean (SD)
Paracetamol 21.2 2,398.6 (960.1) 5.5 (6.3)
NSAIDs
Ibuprofen 17.9 1,428.4 (457.2) 8.5 (13.3)
Metamizol 14.8 2,158.8 (1,598.7) 8.5 (13.3)
Diclofenac 6.3 124.9 (34.8) 8.5 (13.3)
Opiods
Tramadol 27.1 182.9 (110.1) 12.1 (21.5)
Fentanil 8.6 18.5 (25.1) 7.5 (12.9)
AED
Pragabalin 27.2 244.6 (242.5) 13.8 (17.4)
Gabapentin 19.0 1,297.7 (646.9) 9.3 (12.0)
Carbamazepine 5.1 577.1 (313.5) 22.2 (27.5)
Antidepressants
Amitriptyline 10.8 36.2 (27.3) 12.9 (15.4)
Duloxetine 6.1 58.3 (22.0) 8.1 (8.0)
Other drugs
Clonazepam 5.7 2.1 (2.7) 2.2 (1.0)
SD: standard deviation.
was the major cause for uncontrolled pain, regardless of
the clinical entity, but was overrepresented in patients with
plexopathy (96%) and in patients with radiculopathy (91%)
(Table 7). Overall, the treatment satisfaction was low, and the
satisfaction with treatment efficacy was equally low (Table 7).
3.3. Impact of Uncontrolled Pain on Psychological Well-Being
and Disability. More than half of the patients were diagnosed
with depression, and 43% of the patients were diagnosed with
anxiety (Table 8). Sleep was also deeply affected among these
patients. The patients who were referred to pain clinics by
rheumatologists exhibited symptoms that had the greatest
impact on their psychological well-being and sleep (Table 8).
The proportion of disability among patients with uncon-
trolled pain was high, with approximately 50% of the patients
rating their overall health as bad or very bad and 45% noting
that their disease was severely or extremely interfering with
their life (Table 9). The difficulties were present most of the
time (22 of 30 days) and prevented them from executing their
daily activities 15 days amonth.Themost affected dimensions
were life activities either at home or at work (Table 9).
4. Discussion
Our results indicate that uncontrolled neuropathic pain is a
problem that extends intomultiple specialties that address the
issue of chronic pain. Uncontrolled neuropathic pain appears
to affect patients with clinical entities that are a subsidiary
of traumatological care, in which radiculopathy is the most
common cause. Other common causes of uncontrolled pain
are pain of oncological origin and trigeminal neuralgia.
Regardless of the cause and the specialist managing the
patient with uncontrolled pain, we observed the following.
The impact of the disease is high in terms of disrupting the
patients’ psychological well-being and disability; the major
cause of uncontrolled pain is receiving suboptimal treatment;
and the patients are generally dissatisfied with the treatment
received.
Traumatologists were by far the primary referral special-
ists of uncontrolled pain (34%), and radiculopathy was the
most common cause (43%) of uncontrolled pain. These find-
ings are consistent with the most common causes of chronic
pain in the general population.Thus, according to the survey
of pain in Europe, the most frequent location of chronic pain
was back pain (42%) and themore frequent cause of pain was
herniated or deteriorated discs (15%) and traumatic injuries
(12%) [34]. These results overlap with those reported in a
previous study on the etiology of neuropathic pain in patients
who attended pain clinics in Spain [13]. Although radiculopa-
thy is the most common cause of uncontrolled pain because
of its high prevalence as a cause of chronic pain, the presence
of trigeminal neuralgia and pain of oncological origin as
other common causes of uncontrolled pain is likely due to
their refractoriness to current treatments. It is important to
note that patients with uncontrolled oncological pain (i.e.,
pain of malignant origin, radiotherapy- or chemotherapy-
induced) were primarily referred by surgical specialties and,
surprisingly, by primary care physicians. The management
of cancer pain requires the involvement of specialists of
multiple disciplines, and anesthesiologists play a key role [35].
Therefore, we would have expected a higher rate of referrals
of patients with oncological pain from specialties other than
primary care.
The fact that neuropathic pain may be associated with
the presence of anxiety and depressive symptoms and sleep
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disturbances is well known [36–40]. However, it should be
emphasized that high proportions of depression (53%) and
anxiety (43%) were found in our sample of patients with
uncontrolled pain. Anxiety, depressive symptoms, and sleep
disturbances are interrelated in patients with neuropathic
pain and may increase the severity of pain [41–43] and
contribute to the persistence of neuropathic pain [44].There-
fore, the management of uncontrolled pain should focus
not only on the treatment of the underlying disease and its
associated pain but also on the appropriate management of
the accompanying anxiety, depressive symptoms, and sleep
disturbances. Our results emphasize the enormous impact
of uncontrolled pain on the patients’ daily life. Half of
the patients rated their overall health as bad or very bad,
and 45% noted that their condition severely or extremely
interferedwith their life.The interferencewas high, regardless
of the specialty or the pain etiology. However, regarding the
etiology, the interference was higher for the complex regional
pain syndrome and central neuropathic pain. We believe
that this higher interference in these clinical entities more
closely correlated with the underlying disease than to the
pain itself because, with the exception of complex regional
pain syndrome, the etiologies associated with the highest
pain intensity are not those associated with the highest
interference. The difficulties associated with uncontrolled
pain were present most days, and the most severe impact was
on daily activities at home or at work, that is, being totally
unable to conduct their usual activities half of the days in the
previous month. Although it was not specifically evaluated
in our study, as it had been described for neuropathic pain
in general [13, 14, 45], this degree of disability is likely to
contribute to the high costs associated with neuropathic pain.
The investigators from the pain clinics determined that
the main reason for uncontrolled pain was because the
patients were receiving suboptimal treatment; that is, the
patients received either ineffective drugs or subtherapeutic
doses of the drugs. For instance, NSAIDs were used to
treat more than 40% of the patients, and carbamazepine
and oxcarbazepine, the first-line treatments for trigeminal
neuralgia [16], were only used by 56%of the patients with that
condition. However, regarding the latter drug, it is possible
that those patients were receiving a second- or third-line
treatment including surgery. Despite NSAIDs are considered
ineffective and are not recommended for treating neuro-
pathic pain [16, 19, 20, 46, 47], their use is common in patients
with these conditions as it has been reported in several
studies from different countries [18, 48, 49]. Noteworthy,
in our study NSAIDs were used at high doses (e.g., over
1,400mg/day of ibuprofen). The use of NSAIDs contributes
to the suboptimal treatment of neuropathic and increases the
risk of experiencing important adverse reactions. Suboptimal
treatment has been previously described in patients with
neuropathic pain who attended primary care clinics [4, 18, 50,
51]. According to our results, suboptimal treatment seems to
affect all of the specialties involved in the care of patients with
neuropathic pain. Treatment satisfaction was poor across
several specialties and clinical entities. The areas that were
rated with lower satisfaction were treatment effectiveness
and impact on daily activities, and these areas are closely
related. Although satisfaction with medical care received a
higher rating than impact on daily activities, the former issue
seemed to be an area for improvement. Despite the fact that
most patients experienced treatment side-effects according to
the SATMED-Q, medical treatment was rated with greater
satisfaction; however, it should be noticed that acute side
effects were not reflected in that evaluation.
The major limitation in our study was the definition of
uncontrolled pain that was entirely based on the subjective
evaluation of the investigators from the pain clinics. We
accepted this subjective evaluation because there is no stan-
dard definition of refractory neuropathic pain [21]. Recently,
a group of experts tried to achieve consensus on this matter
[52]; according to that consensus, to classify a neuropathic
pain as refractory, “it should have had a trial of treatmentwith
at least four drugs of known effectiveness, each drug should
have been tried at least three months or until side effects
prevent adequate dosage, and despite the above treatment,
the intensity of pain should have reduced by less than 30%,
should remain at a level of at least 5 on a 0–10 scale, and/or
should continue to contribute significantly to poor quality of
life” [52]. Because the patients in our study were considered
to have received suboptimal treatment, it is difficult to
meet those criteria. However, the patients’ pain was clearly
persistent, severe, disabling, and, therefore, uncontrolled.
Overall, our results showed that uncontrolled neuro-
pathic pain is a common phenomenon among the specialties
that address these clinical entities, and regardless of its
etiology, uncontrolled neuropathic pain is associated with
a dramatic impact on patient well-being. A definite need
exists for improving the management of neuropathic pain
in all of these specialties, which should not be limited to
the improvement of pain but also should be extended to the
management of psychological symptoms and possibly to the
improvement of the doctor-patient relationship.
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